News
Vizgen®, Ultivue Merge, Further Consolidating Spatial Biology
Read More
News
Two Cambridge Biotechs Merge
Read More
News
Vizgen® to Merge With Ultivue, Announces Series D Financing
Read More
News
Vizgen® and Ultivue Merge to Enable Deeper Insights into Disease Mechanisms and Drive Innovation in Spatial Multiomics
Read More
News
Spatial biology companies Vizgen® and Ultivue merge amid ongoing lawsuits
Read More
Press Releases
Vizgen® to Present Clinical Research Case Study and Research Findings at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Read More
News
Top 10 Spatial Biology Companies of 2024
Read More
Vizgen Views
How does the tumor microenvironment change after treatment with a new drug candidate?
Read More
Press Releases
Vizgen® Launches Certified Service Provider (CSP) Program, Expanding Access to Single-Cell Spatial Genomics Technology
Read More
Expert Spotlight
For which indications is my drug candidate most efficacious?
Read More
Top